Navigation Links
Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
Date:6/18/2013

s a growing therapeutic area. It is currently estimated at about US $10 billion and is expected to continue expanding for the foreseeable future.  

About Mapi-Pharma

Mapi Pharma (Mapi) is an international pharmaceutical company specializing in complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, high development barrier generics and novel finished dosage forms based on selected drug delivery systems. Mapi is focused on developing innovative delivery systems for pharmaceuticals such as long acting depot injections. Mapi has an extensive pipeline of medications that will follow the FDA regulatory pathway 505(b)(2). The company is built on the strong chemical and pharmaceutical R&D capabilities of its founders, a deep understanding of the global market and of regulatory needs and its ability to foster local cooperation and enduring relationships in all of the countries in which it is present. Mapi is dedicated to providing generic and innovative intermediates & APIs as well as developing finished dosage forms - either to Mapi's internal API program, as a vertically integrated company, or generically, to other leading brands. Mapi is headquartered in Israel.  It has R&D facilities in Israel, China and Germany and is currently building an API manufacturing site in Neot Hovav, Israel's designated chemical park. The company has a strong IP position, filing more than 20 patent applications for APIs and formulations in less than three years since it began operations. For more information: http://www.mapi-pharma.com

Press Contact:
Marjie Hadad
Media Liaison
Mapi Pharma
marjie@mapi-pharma.com
+972-54-536-5220


'/>"/>
SOURCE Mapi Pharma Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... , Jan. 14, 2014 The largest ... research medicinal plants and therapeutic derivatives thereof has ... professionals, and researchers about the challenges of adulterated ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society for ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... MOUNTAIN VIEW, Calif., Feb. 25 Alexza,Pharmaceuticals, ... that it has initiated,its first Phase 3 ... an inhalation product candidate being developed for ... schizophrenia or bipolar disorder. Alexza,believes the novel, ...
... data by Dr. J.,Barthelow Classen shows that vaccines ... a strong family history of insulin dependent,diabetes. Previous ... recipients at a rate which exceeds their benefit ... particularly toxic to those,with a strong family history ...
... falling on only 9 percent of Californias Mojave ... electricity needs if the energy could be efficiently ... cell technologies are too expensive and inefficient for ... University researchers has developed a new anode coating ...
Cached Biology Technology:Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Special coating greatly improves solar cell performance 2
(Date:4/24/2014)... droplet of clear liquid can bend light, acting as ... have developed a new process to create inexpensive high ... apiece. , Because they,re so inexpensive, the lenses ... tools to detect diseases in the field, scientific research ... education in classrooms. , "What I,m really excited ...
(Date:4/23/2014)... to early fetal death according to a new study ... Hospital Los Angeles and Ulaanbaatar, Mongolia the coldest ... published today in the journal BMC Pregnancy and ... seasonal ambient air pollutants and pregnancy loss in Ulaanbaatar ... highest levels of air pollution of all world capitals, ...
(Date:4/23/2014)... release is available in French and ... Montreal, 23 April 2014Today, the CEC released its Conservation ... Collaborative Approach to Conservation, which identifies 29 priority conservation ... that includes 11 different protected areas in the states ... highly diverse arid and semi-arid habitats inhabited by rare ...
Breaking Biology News(10 mins):Bake your own droplet lens 2Bake your own droplet lens 3Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3
... Spanish . , Geraniums may hold the key ... 300 plant species and costs the ornamental plant industry $450 ... Agricultural Research Service (ARS). The beetle, Popillia ... plants, including ornamentals, soybean, maize, fruits and vegetables. But within ...
... book, "Strategic Bargaining and Cooperation in Greenhouse Gas Mitigations," ... work together to reduce carbon dioxide emissions. He also ... fuels whether they contribute to climate change or ... and I,m not making a scientific judgment here ...
... the expense of costly treatments for cancer and ... by growing these human therapeutic proteins in algaerapidly ... attention for their ability to produce biofuels. ... this week in Plant Biotechnology Journal, which sought ...
Cached Biology News:Geraniums could help control devastating Japanese beetle 2Cool model for a hot planet 2Cool model for a hot planet 3Study shows potential for using algae to produce human therapeutic proteins 2Study shows potential for using algae to produce human therapeutic proteins 3Study shows potential for using algae to produce human therapeutic proteins 4
Mouse monoclonal [2G1] to Vancomycin ( Abpromise for all tested applications)....
Rab1A...
... to LYZL6 ( Abpromise for ... Antigen: Synthetic peptide: DWLCL AFVE ... corresponding to amino acids 46-100 of ... Gene ID: 57151 ...
Request Info...
Biology Products: